natgillin/translations-raw huggingface dataset:
• abnormiteter i ørerne (f.eks. abnormt formet eller manglende ydre øre), tillukning af øregangen
• Abnormalities of the ear (e.g. abnormally formed or absent externalear), external auditory canal atresia (middle ear);
Hver flaske indeholder 35 g mycophenolatmofetil i 110 g pulver til oral suspension.
Each bottle contains 35 g mycophenolate mofetil in 110 g powder for oral suspension.
Middelværdien for plasma-MPAG-AUC0-12 timer var 2-3 gange højere end hos post-transplanterede patienter uden forsinket transplantatfunktion.
Mean plasma MPAG AUC0-12h was 2 - 3-fold higher than in post-transplant patients without delayed graft function.
• Hold godt omkring selve dispenseren og træk dispenseren langsomt ud af flaskeadaptoren.
Holding onto the body of the dispenser, carefully pull the dispenser out of the bottle adapter.
• Brug ikke CellCept efter den udløbsdato, der står på pakningen efter EXP.
• Do not use the capsules after the expiry date stated on the carton (EXP).
Når behandlingen initieres, skal fertile kvinder informeres om den øgede risiko for abort og medfødte misdannelser, og de skal vejledes omkring prævention og graviditetsplanlægning.
Female patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counseled regarding pregnancy prevention and planning.
Den anbefalede dosis på 1 g administreret to gange daglig til nyre- eller levertransplanterede patienter er passende til ældre.
The recommended dose of 1 g administered twice a day for renal or hepatic transplant patients is appropriate for the elderly.
Den systemiske eksponering af denne dosis var ca. 0,5 gange den kliniske eksponering af den anbefalede kliniske dosis på 2 g daglig.
The systemic exposure at this dose was approximately 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day.
Hudlidelser såsom: • akne, forkølelsessår, helvedesild (herpes zoster), øget hudvækst, hårtab, udslæt, kløe.
Skin problems such as: acne, cold sores, shingles, skin growth, hair loss, rash, itching.
Indholdet af hvert hætteglas med CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning, skal rekonstitueres med 14 ml 5 % glucoseinfusionsvæske.
The contents of CellCept 500 mg powder for concentrate for solution for infusion vials must be reconstituted with 14 mL of glucose intravenous infusion 5% each.
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/96/005/006 CellCept (1 flaske 110 g)
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/006 CellCept (1 bottle 110g)
Hvis infusionsopløsningen ikke er fremstillet umiddelbart før administrationen skal infusion af infusionsopløsningen påbegyndes senest 3 timer efter fremstillingen og opløsning af lægemidlet.
Reconstituted solution and infusion solution: If the infusion solution is not prepared immediately prior to administration, the commencement of administration of the infusion solution should be within 3 hours from reconstitution and dilution of the medicinal product.
150 (3 pakker af 50) tabletter.
(150 (3x50) tablets multipack)
Lægemidler som påvirker MPAs enterohepatiske kredsløb (f.eks. colestyramin, antibiotika) bør anvendes med forsigtighed, da de potentielt kan reducere plasmaniveauet og virkningen af CellCept (se også pkt.
Drugs which interfere with MPA's enterohepatic cycle (e.g. cholestyramine, antibiotics) should be used with caution due to their potential to reduce the plasma levels and efficacy of CellCept (see also section 4.5).
• Den første dosis gives inden for 5 dage efter transplantationen.
The first dose is given within 5 days of the transplant operation.
• Aktivt stof: Mycophenolatmofetil.
• The active substance is mycophenolate mofetil.
Den i dyre-carcinogenicitetsstudier højest testede dosis resulterede i ca. 2 - 3 gange den systemiske eksponering (AUC eller Cmax), der er observeret hos nyretransplanterede patienter, der fik den anbefalede kliniske dosis på 2 g daglig.
The highest dose tested in the animal carcinogenicity studies resulted in approximately 2 - 3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/day.
Hætteglasset bortkastes, hvis der ses partikler eller misfarvning.
Discard the vial if particulate matter or discoloration is observed.
Der blev ikke set kliniske konsekvenser af de farmakokinetiske lægemiddelinteraktioner ved sammenligning af hyppigheden af afstødning af transplantat eller tab af transplantat eller bivirkningsprofilen mellem Cellcept-patienter med og uden samtidig telmisartan-medicinering.
When comparing rates of transplant rejection, rates of graft loss or adverse event profiles between CellCept patients with and without concomitant telmisartan medication, no clinical consequences of the pharmacokinetic drug-drug interaction were seen.
Kapselskaller gelatine indigotin (E132) gul jernoxid (E172) rød jernoxid (E172) titandioxid (E171) sort jernoxid (E172) kaliumhydroxid shellac
Capsule shells gelatin indigo carmine (E132) yellow iron oxide (E172) red iron oxide (E172) titanium dioxide (E171) black iron oxide (E172) potassium hydroxide shellac.
Svært nedsat leverfunktion Dosisjustering er ikke nødvendig hos nyretransplanterede patienter med svær leverparenkymlidelse.
Severe hepatic impairment No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
Hyperkaliæmi
Hyperlipidemia
• Holdbarheden af den blandede suspension er 2 måneder.
• The shelf-life of the reconstituted suspension is two months.
LÆGEMIDLETS NAVN CellCept 1 g/5 ml pulver til oral suspension.
NAME OF THE MEDICINAL PRODUCT CellCept 1 g/5 ml powder for oral suspension.
Efter markedsføring er der blevet observeret medfødte misdannelser hos børn af patienter, der har været eksponeret for CellCept i kombination med andre immunsuppressiva (se pkt.
Congenital malformations have been observed post-marketing in children of patients exposed to CellCept in combination with other immunosuppressants, see section 4.6.
Til patienter med en legemsoverflade > 1,5 m2 kan der ordineres CellCept-kapsler i en dosis på 1 g to gange daglig (daglig dosis: 2 g).
Patients with a body surface area greater than 1.5 m2 may be prescribed CellCept capsules at a dose of 1 g twice daily (2 g daily dose).
Hypocalcæmi
Hypocalcemia
CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning, findes i pakninger med 4 hætteglas.
CellCept 500 mg powder for concentrate for solution for infusion is available in packs containing 4 vials.
Lymfoproliferativ sygdom
Lymphoproliferative disorder
• Den daglige dosis er 2 g af medicinen indtaget som 2 separate doser.
The daily dose is 2 g of the medicine taken as 2 separate doses.
Patienter der får immunsuppressiv behandling med kombinationer af lægemidler, inklusiv CellCept, har forhøjet risiko for at udvikle lymfomer og andre maligniteter, særligt i huden (se pkt.
Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4).
Der er rapporteret hypogammaglobulinæmi i forbindelse med tilbagevendende infektioner hos patienter, der har fået CellCept i kombination med andre immunsuppressiva.
There have been reports of hypogammaglobulinaemia in association with recurrent infections in patients receiving CellCept in combination with other immunosuppressants.
5 ml af den rekonstituerede suspension indeholder 1 g mycophenolatmofetil.
5 mL of the reconstituted suspension contains 1 g of mycophenolate mofetil.
I kontrollerede kliniske studier hos nyre-, hjerte- og levertransplanterede patienter, som blev fulgt i mindst 1 år, var de almindeligste opportunistiske infektioner hos patienter, som fik CellCept (2 g eller 3 g daglig) sammen med andre immunsupprimerende stoffer, mukokutane candidainfektioner, CMV-viræmi/syndrom og herpes simplex-infektioner.
The most common opportunistic infections in patients receiving CellCept (2 g or 3 g daily) with other immunosuppressants in controlled clinical trials in renal, cardiac and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex.
Meget almindelig Ikke almindelig
Very Common Uncommon
Pædiatrisk population Der er ingen data vedrørende levertransplantationer hos pædiatriske patienter.
Paediatric population No data are available for paediatric hepatic transplant patients.
Den anbefalede dosis på 1 g to gange daglig til nyretransplanterede patienter og 1,5 g to gange daglig til hjerte- eller levertransplanterede patienter er passende til ældre.
The recommended dose of 1 g administered twice a day for renal transplant patients and 1.5 g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly.
I kontrollerede kliniske studier hos nyre- og levertransplanterede patienter, som blev fulgt i mindst 1 år, var de almindeligste opportunistiske infektioner hos patienter, som fik CellCept (2 g eller 3 g daglig) sammen med andre immunsupprimerende stoffer, mukokutane candidainfektioner, CMV-viræmi/syndrom og herpes simplex-infektioner.
The most common opportunistic infections in patients receiving CellCept (2 g or 3 g daily) with other immunosuppressants in controlled clinical trials in renal and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex.
LÆGEMIDLETS NAVN CellCept 1 g/5 ml pulver til oral suspension mycophenolatmofetil
NAME OF THE MEDICINAL PRODUCT CellCept 1 g/5 ml powder for oral suspension mycophenolate mofetil
• Hver flaske med 110 g pulver til oral suspension indeholder 35 g mycophenolatmofentil.
• Each bottle of 110 g powder for oral suspension contains 35 g of mycophenolate mofetil. Reconstitute with 94 mL of purified water.
CellCept-kapsler må kun ordineres til patienter med en legemsoverflade på mindst 1,25 m2. Til patienter med en legemsoverflade på 1,25-1,5 m2 kan der ordineres CellCept-kapsler i en dosis på 750 mg to gange daglig (daglig dosis: 1,5 g).
Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed CellCept capsules at a dose of 750 mg twice daily (1.5 g daily dose).
CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning
CellCept 500 mg powder for concentrate for solution for infusion
Sådan skal du tage CellCept
How to take CellCept
LÆGEMIDLETS NAVN CellCept 500 mg filmovertrukne tabletter.
NAME OF THE MEDICINAL PRODUCT CellCept 500 mg film-coated tablets.
4.3), inden behandling med CellCept påbegyndes, under behandlingen og i seks uger efter behandlingsophør, medmindre seksuel afholdenhed er den valgte form for prævention.
Therefore, women with childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting CellCept therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception.
Synk kapslerne hele med et glas vand
Swallow your capsules whole with a glass of water Do not break or crush them
Medicinens fulde navn er CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning.
The full name of your medicine is CellCept 500 mg powder for concentrate for solution for infusion.
Da MPAG-plasmakoncentrationer forhøjes ved nedsat nyrefunktion, ligesom aciclovir-koncentrationerne bliver det, er der en mulighed for, at mycophenolatmofetil og aciclovir, eller dets prodrugs, f.eks. valaciclovir, vil konkurrere om den tubulære sekretion, og der kan ske yderligere forhøjelser af koncentrationerne af begge stoffer.
Because MPAG plasma concentrations are increased in the presence of renal impairment, as are aciclovir concentrations, the potential exists for mycophenolate mofetil and aciclovir, or its prodrugs, e.g. valaciclovir, to compete for tubular secretion, and further increases in concentrations of both substances may occur.
DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF TILLADELSEN
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 February 1996
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) CellCept 1 g/5 ml pulver til oral suspension mycophenolatmofetil
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION CellCept 1 g/5 ml powder for oral suspension mycophenolate mofetil
Holdbarheden af den rekonstituerede orale suspension er 2 måneder.
The shelf-life of the reconstituted suspension is 2 months.
Hjerte Takykardi
Cardiac disorders Tachycardia
LÆGEMIDLETS NAVN, STYRKE OG/ELLER ADMINISTRATIONSVEJ(E) CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning mycophenolatmofetil
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION CellCept 500 mg powder for concentrate for solution for infusion mycophenolate mofetil
Børn • Der er ingen information om brug af CellCept til hjertetransplanterede børn.
There is no information for the use of CellCept in children with a heart transplant.
I nogle af disse tilfælde blev serum-IgG normaliseret, når Cellcept blev erstattet af alternative immunsuppressiva.
In some of these cases switching CellCept to an alternative immunosuppressant resulted in serum IgG levels returning to normal.
Meget almindelig Meget almindelig Meget almindelig
Very Common Very Common Very Common
A. FREMSTILLERE ANSVARLIGE FOR BATCHFRIGIVELSE Navn og adresse på den fremstiller, der er ansvarlig for batchfrigivelse - CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning - CellCept 1 g/5 ml pulver til oral suspension:
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacture(s) responsible for batch release CellCept 500 mg powder for concentrate for solution for infusion CellCept 1 g/5 ml powder for oral suspension: Roche Pharma AG, Emil-Barell-Str. 1, 79639 Grenzach-Wyhlen, Germany.
Forhøjet laktatdehydrogenase
Blood lactate dehydrogenase increased
4.2) forventes det at samtidig administration af disse stoffer (som konkurrerer om mekanismerne for renal tubulær sekretion) vil resultere i stigninger af MPAG- og ganciclovirkoncentrationerne.
Based on the results of a single dose administration study of recommended doses of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of CellCept (see section 4.2) and ganciclovir, it is anticipated that co-administration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration.
5 ml af den rekonstituerede suspension indeholder 1 g mycophenolatmofentil.
5 mL of the reconstituted suspension contain 1 g of mycophenolate mofetil.
• Den daglige dosis er 15 ml suspension (3 g af medicinen) indtaget som 2 separate doser.
• The daily dose is 15 mL suspension (3 g of the medicine) taken as 2 separate doses.
mycophenolatmofetil.
(mycophenolate mofetil)
Sikkerhedsforanstaltninger, der skal tages før håndtering og administration af lægemidlet Da mycophenolatmofetil har udvist fosterbeskadigende virkning hos rotter og kaniner, skal inhalation undgås og undgå, at hud og slimhinder kommer i direkte kontakt med det tørre pulver og undgå, at hud kommer i direkte kontakt med den rekonstituerede suspension.
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, avoid inhalation or direct contact with skin or mucous membranes of the dry powder as well as direct contact of the reconstituted suspension with the skin.
Ældre patienter som får CellCept som led i et immunsuppressivt kombinationsregime, kan have større risiko for visse infektioner (inklusive vævsinvasiv sygdom forårsaget af cytomegalovirus) og muligvis gastrointestinal blødning og lungeødem, sammenlignet med yngre individer.
Elderly patients receiving CellCept as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals.
Samtidig administration af lægemidler, der påvirker glukuronidering af MPA, kan ændre MPAeksponeringen.
Medicinal products that affect glucuronidation (e.g. isavuconazole, telmisartan) Concomitant administration of drugs affecting glucuronidation of MPA may change MPA exposure.
mycophenolatmofetil oralt to gange daglig, var typen og hyppigheden af bivirkninger generelt den samme som dem, der observeredes hos voksne patienter, som fik 1 g CellCept to gange daglig.
The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600 mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1 g CellCept twice daily.
Den systemiske eksponering af denne dosis repræsenterer 2 - 3 gange den kliniske eksponering ved den anbefalede kliniske dosis på 2 g daglig til nyretransplanterede patienter og 1,3 - 2 gange den kliniske eksponering ved den anbefalede kliniske dosis på 3 g daglig til hjertetransplanterede patienter.
The systemic exposure at this dose represents 2 - 3 times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3 - 2 times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients.
Der er rapporteret om enkelte tilfælde af interstitiel lungesygdom og lungefibrose hos patienter, som fik Cellcept i kombination med andre immunsuppressiva.
There have been isolated reports of interstitial lung disease and pulmonary fibrosis in patients treated with CellCept in combination with other immunosuppressants, some of which have been fatal.
Den i dyre-carcinogenicitetsstudier højest testede dosis resulterede i ca. 2 - 3 gange den systemiske eksponering (AUC eller Cmax), der er observeret hos nyretransplanterede patienter, der fik den anbefalede kliniske dosis på 2 g daglig og 1,3 - 2 gange den systemiske eksponering (AUC eller Cmax) observeret hos hjertetransplanterede patienter, der fik den anbefalede kliniske dosis på 3 g daglig.
The highest dose tested in the animal carcinogenicity studies resulted in approximately 2 - 3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/day and 1.3 - 2 times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3 g/day.
Hypogammaglobulinæmi er rapporteret hos patienter, der har fået Cellcept i kombination med andre immunsuppressiva.
Hypogammaglobulinaemia has been reported in patients receiving CellCept in combination with other immunosuppressants.
Rekonstituer og fortynd før brugen Læs indlægssedlen inden brug
METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous infusion only Reconstitute and dilute before use Read the package leaflet before use
CellCept filmovertrukne tabetter indeholder:
Contents of the pack and other information What CellCept film coated tablet contains
LÆGEMIDLETS NAVN CellCept 250 mg kapsler mycophenolatmofetil
NAME OF THE MEDICINAL PRODUCT CellCept 250 mg capsules mycophenolate mofetil
Der blev ikke set signifikante forskelle i hyppigheden af afstødning eller tab af transplantat hos Cellcept-patienter, som tog protonpumpehæmmer versus Cellcept-patienter, som ikke tog protonpumpehæmmer.
When comparing rates of transplant rejection or rates of graft loss between CellCept patients taking PPIs vs. CellCept patients not taking PPIs, no significant differences were seen.
Føde har ingen effekt på absorptionen (MPA-AUC) af mycophenolatmofetil, når det gives i doser på 1,5 g to gange daglig til nyretransplanterede patienter.
The mean bioavailability of oral mycophenolate mofetil, based on MPA AUC, is 94% relative to IV mycophenolate mofetil. Food had no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil when administered at doses of 1.5 g BID to renal transplant patients.
Fortsæt dog behandlingen, indtil du ser lægen.
However, keep taking CellCept until you see him or her.
I et studie af fertilitet og reproduktion udført på hunrotter forårsagede orale doser på 4,5/mg/kg/dag misdannelser (inkl.
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg-/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
Hypomagnesæmi
Hypomagnesemia
b) Inspicer opløsningen for partikler og misfarvning.
Inspect the infusion solution for particulate matter or discoloration.
• Den daglige dosis er 10 ml suspension (2 g af medicinen) indtaget som 2 separate doser.
The daily dose is 10 mL suspension (2 g of the medicine) taken as 2 separate doses.
Ældre patienter kan have større risiko for bivirkninger såsom visse infektioner (inklusiv vævsinvasiv sygdom forårsaget af cytomegalovirus) og muligvis gastrointestinal blødning og lungeødem, sammenlignet med yngre patienter (se pkt.
Elderly patients may be at an increased risk of adverse events such as certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared with younger individuals (see section 4.8).
Den anbefalede dosis CellCept til infusion til levertransplanterede patienter er 1 g to gange daglig (en døgndosis på 2 g).
The recommended dose of CellCept for infusion in hepatic transplant patients is 1 g administered twice daily (2 g daily dose).
I et studie af fertilitet og reproduktion udført på hunrotter forårsagede orale doser på 4,5 mg/kg/dag misdannelser (inkl.
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
Denne medicin indeholder mindre end 1 mmol natrium (23 mg) pr. tablet, dvs. den er i det væsentlige natriumfri.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hvert hætteglas indeholder 500 mg mycophenolatmofetil som hydrochlorid.
STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains the equivalent of 500 mg mycophenolate mofetil as the hydrochloride salt.
Denne medicin indeholder mindre end 1 mmol natrium (23 mg) pr. kapsel, dvs. den er i det væsentlige natriumfri.
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium-free'.
Sikkerhedsforanstaltninger, der skal tages før håndtering og administration af lægemidlet Da mycophenolatmofetil har udvist fosterbeskadigende virkning hos rotter og kaniner, må CellCept tabletter ikke knuses.
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, CellCept tablets should not be crushed.
• Den daglige dosis er 4 tabletter (2 g af medicinen) indtaget som 2 separate doser.
The daily dose is 4 tablets (2 g of the medicine) taken as 2 separate doses.
CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning, skal rekonstitueres og yderligere fortyndes med 5 % glucose intravenøs infusionsvæske før indgift til patienten.
CellCept 500 mg powder for concentrate for solution for infusion must be reconstituted and further diluted with glucose intravenous infusion 5% prior to administration to the patient (see section 6.6).
Der findes ingen data for levertransplanterede patienter med svær, kronisk nedsat nyrefunktion.
No data are available for hepatic transplant patients with severe chronic renal impairment.
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE) EU/1/96/005/005 CellCept (4 hætteglas)
MARKETING AUTHORISATION NUMBER(S) EU/1/96/005/005 CellCept (4 vials)
Den anbefalede dosis til nyretransplanterede patienter er 1 g administreret to gange daglig (en døgndosis på 2 g).
The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose).
cyster og polypper) Benignt neoplasme af huden
Neoplasms benign, malignant and unspecified (including cysts and polyps) Benign neoplasm of skin
LÆGEMIDLETS NAVN CellCept 500 mg pulver til koncentrat til infusionsvæske, opløsning.
NAME OF THE MEDICINAL PRODUCT CellCept 500 mg powder for concentrate for solution for infusion.